The miRAO checks whether each miRNA has been validated with targets according to a specified miRNA-target database (Additional file 1) and whether each miRNA has validated transcription factors (TFs) according to the TransmiR database (version 1.2), which provides detailed information regarding type and effect of transcriptional regulations on miRNAs with corresponding literature [ 34].
Use of RNAi libraries for genome-wide screens is complicated by the presence of RNAi sequences that either do not result in efficient depletion, have off-target effects, or that cannot be validated with siRNAs targeting different sequences of the same gene.
In a future research step, this model will be validated with a questionnaire survey targeting non-expert users, i.e. average consumers, on the construction market in Germany.
Although MAP3K9 is a predicted target of miR-34a, direct targeting could not be validated with luciferase reporter assays.
Thus, candidate target genes are required to be validated with highly reliable biotechniques, such as qRT-PCR [ 26].
However, our reported changes of trastuzumab mediated differential gene expression in cardiomyocytes were validated with additional ERBB2 targeted compounds and we also observed considerable overlap in ERBB2-overexpressing cancer cell lines which we interpret as strong evidence that ERBB2 inhibition is responsible for our reported changes in gene expression.
The first version of miRanda was published in 2003, and the results were validated with microRNA targets in Drosophila melanogaster [ 6].
The target recognition method and hence the designed target is validated with experimental results.
Apart from the correlation approach, the accuracy of the proposed model was validated with corresponding experimental observations of target design concretes followed by the model parameters estimation with 95% confidence interval.
Then, this model has been validated with some real profilings carried out on the target MB with and without floating point unit (FPU).
